A detailed history of Eagle Asset Management Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Eagle Asset Management Inc holds 294,280 shares of PTGX stock, worth $11.5 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
294,280
Previous 357,633 17.71%
Holding current value
$11.5 Million
Previous $12.4 Million 6.72%
% of portfolio
0.08%
Previous 0.07%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$33.72 - $47.33 $2.14 Million - $3 Million
-63,353 Reduced 17.71%
294,280 $13.2 Million
Q2 2024

Aug 12, 2024

BUY
$24.66 - $34.8 $8.82 Million - $12.4 Million
357,633 New
357,633 $12.4 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.92B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Eagle Asset Management Inc Portfolio

Follow Eagle Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.